NCT06976190View on ClinicalTrials.gov

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

December 31, 2030

Conditions
Recurrent or Metastatic Nasopharyngeal Carcinoma
Interventions
DRUG

MRG003 + Pucotenlimab

MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.

DRUG

Gemcitabine, Docetaxel, or Capecitabine

"Gemcitabine will be administrated via intravenous infusion at 1000 mg/m2 once on Day 1 and 8 of every 3 weeks (21-day cycle).~Docetaxel will be administrated via intravenous infusion at 75 mg/m2 once on Day 1 of every 3 weeks (21-day cycle).~Capecitabine will be administrated orally at 1000 mg/m2 twice a day for Day 1 to 14 of every 3 weeks (21-day cycle)."

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Shanghai Miracogen Inc.

INDUSTRY